Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Precision BioSciences (DTIL)
NASDAQ:DTIL
Holding DTIL?
Track your performance easily
DTIL Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.13 - $19.43
Previous Close$4.72
Volume705.51K
Average Volume (3M)103.01K
Market Cap
$35.29M
Enterprise Value-$35.61M
Total Cash (Recent Filing)$101.20M
Total Debt (Recent Filing)$30.31M
Price to Earnings (P/E)92.4
Beta2.34
Next Earnings
Mar 18, 2025EPS Estimate
-$2.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding7,671,059
10 Day Avg. Volume124,049
30 Day Avg. Volume103,011
Standard Deviation0.24
R-Squared0.09
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)0.56
Price to Sales (P/S)0.47
Price to Cash Flow (P/CF)-1.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.44
Enterprise Value/Gross Profit-0.73
Enterprise Value/Ebitda-3.60
Forecast
1Y Price Target
$41.33Price Target Upside775.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Precision BioSciences News
PremiumCompany Announcements
Precision BioSciences Advances Gene Editing Trials Globally
Bulls Say, Bears Say
Bulls Say
Clinical MilestonesPrecision Bio is on track to hit multiple milestones to validate their ARCUS genome editing technology, which is expected to firmly position them in the gene editing space.
Financial StabilityWith a high cash position of approximately $121 million, Precision Bio provides financial stability and runway into the second half of 2026.
Innovative TechnologyARCUS is a unique approach in a space crowded with CRISPR-based gene editing, offering distinct advantages by not requiring a nucleic acid for targeting and can penetrate mitochondrial membranes.
Bears Say
Clinical Safety ConcernsNew safety concerns with in vivo gene editing and potential failure to execute editing in patients raise significant clinical risks.
Efficacy And Safety ChallengesTrial design aiming to enhance cumulative editing efficiency may inadvertently increase liver toxicity, presenting a safety challenge.
Regulatory And Competitive RisksDelays in IND submissions and competitive pressure from peer gene editing companies could hinder progress and market positioning.
---
Ownership Overview
2.36% Insiders
4.34% Mutual Funds
22.18% Other Institutional Investors
67.91% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DTIL FAQ
What was Precision BioSciences’s price range in the past 12 months?
Precision BioSciences lowest stock price was $4.13 and its highest was $19.43 in the past 12 months.
What is Precision BioSciences’s market cap?
Currently, no data Available
When is Precision BioSciences’s upcoming earnings report date?
Precision BioSciences’s upcoming earnings report date is Mar 18, 2025 which is in 86 days.
How were Precision BioSciences’s earnings last quarter?
Precision BioSciences released its earnings results on Nov 04, 2024. The company reported -$2.25 earnings per share for the quarter, missing the consensus estimate of -$2.136 by -$0.114.
Is Precision BioSciences overvalued?
According to Wall Street analysts Precision BioSciences’s price is currently Undervalued.
Does Precision BioSciences pay dividends?
Precision BioSciences does not currently pay dividends.
What is Precision BioSciences’s EPS estimate?
Precision BioSciences’s EPS estimate is -$2.25.
How many shares outstanding does Precision BioSciences have?
Precision BioSciences has 7,671,059 shares outstanding.
What happened to Precision BioSciences’s price movement after its last earnings report?
Precision BioSciences reported an EPS of -$2.25 in its last earnings report, missing expectations of -$2.136. Following the earnings report the stock price went down -8.093%.
Which hedge fund is a major shareholder of Precision BioSciences?
Among the largest hedge funds holding Precision BioSciences’s share is Perceptive Advisors LLC. It holds Precision BioSciences’s shares valued at 4M.
---
Precision BioSciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$41.33 (775.64% Upside)
$41.33 (775.64% Upside)
Insider Transactions
Bought Shares
Worth $20.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.2%
Last 30 Days ▼ 7.6%
Last 30 Days ▼ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.30%
12-Months-Change
Fundamentals
Return on Equity
24.44%
Trailing 12-Months
Asset Growth
-6.75%
Trailing 12-Months
Company Description
Precision BioSciences
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.
---
DTIL Stock 12 Month Forecast
Average Price Target
$41.33
▲(775.64% Upside)
Technical Analysis
Arcturus Therapeutics
―
Adaptimmune Therapeutics
―
Caribou Biosciences
―
Editas Medicine
―
Best Analysts Covering DTIL
1 Year
1 Year Success Rate
0/24 ratings generated profit
1 Year Average Return
-59.62%
reiterated a buy rating 2 months ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -59.62% per trade.
---